Does Methotrexate Cause Permanent Kidney Damage?
Yes, methotrexate can lead to permanent kidney damage, particularly with high doses or in patients with pre-existing kidney issues. It causes acute kidney injury through precipitation of the drug or its metabolites in renal tubules, leading to tubular necrosis. In severe cases, this results in chronic kidney disease or irreversible renal failure, especially if not managed promptly.[1][2]
How Common Is Kidney Damage from Methotrexate?
Kidney toxicity occurs in 1-5% of patients on high-dose methotrexate (e.g., for cancer), but it's rarer (<1%) with low-dose regimens for rheumatoid arthritis or psoriasis. Risk rises with doses over 1 g/m², dehydration, or concurrent nephrotoxic drugs like NSAIDs.[3][4] Permanent damage is uncommon but documented in case reports of patients requiring long-term dialysis post-acute injury.[1]
What Are the Warning Signs of Kidney Problems?
Early signs include rising serum creatinine, decreased urine output, electrolyte imbalances (high potassium, low calcium), and mucosal ulcers. Monitor levels closely during high-dose therapy; leucovorin rescue mitigates but doesn't eliminate risk. Baseline kidney function tests are standard before starting.[2][5]
Which Patients Are at Highest Risk?
Those with reduced glomerular filtration rate (GFR <60 mL/min), older age, diabetes, hypertension, or third-space fluid shifts (e.g., ascites). Genetic factors like MTHFR polymorphisms may impair drug clearance, worsening outcomes. Low-dose users rarely see permanent effects if hydrated and dosed by body surface area.[3][6]
Can Kidney Damage Be Prevented or Reversed?
High urine output (via hydration and alkalinization to pH >7), leucovorin, and glucarpidase for delayed clearance prevent most cases. Acute damage often reverses within days to weeks if caught early, but glomerular scarring can persist, leading to permanent decline. Dialysis supports recovery but doesn't guarantee it.[4][5]
What Do Guidelines Say About Monitoring?
NCCN and ACR recommend pre-treatment CrCl assessment, weekly monitoring for low-dose, and 48-hour post-infusion checks for high-dose. Discontinue if CrCl drops >50%.[2][7] Patient reports on forums highlight rare but real long-term issues, often tied to non-adherence to monitoring.
[1]: UpToDate: Methotrexate drug information
[2]: Medscape: Methotrexate toxicity
[3]: NEJM: High-dose methotrexate nephrotoxicity
[4]: FDA Label: Methotrexate
[5]: American College of Rheumatology: Methotrexate guidelines
[6]: PubMed: Risk factors for MTX nephrotoxicity
[7]: NCCN Guidelines: Acute lymphoblastic leukemia